

# IN THE SPECIFICATION

Please insert the attached sequence Listing into the above-identified patent application.

On page 9, please delete and replace the current version of Table 1 with the following replacement Table 1. Pursuant to 37 C.F.R. § 1.121, the following is a clean version of the replacement Table 1. A marked-up version of the replacement Table 1 is attached on a separate sheet.

**Table 1.** Interpretation of mass-spectrometrical data of TC-1 and TC-2: comparison with CTAP III

Component	Mol. weight (Da)		Sequence of	
	MALDI/ES	Calc	N-terminus	C-terminus
CTAP-III		9287,2	NLAKGKEESLDSPLYAELR .... (SEQ ID NO: 1)	AGDESAD
TC-1a	7106,2	7105,8	AELR .... (SEQ ID NO: 2)	AG
TC-1b	7226,7	7220,9	AELR .... (SEQ ID NO: 2)	AGD
TC-1*	7436,3	7437,5	AELR .... (SEQ ID NO: 3)	AGDES
TC-1d	7601,0	7600,7	Y AELR .... (SEQ ID NO: 4)	AGDES (SEQ ID NO: 5)
TC-2	9100,5	9101,6	NLAKGKEESLDSPLYAELR .... (SEQ ID NO: 6)	AGDES

Please delete and replace the current version of the paragraph entitled EXAMPLE 2 which bridges pages 10 and 11 with the following replacement paragraph. Pursuant to 37 C.F.R. § 1.121, the following is a clean version of the replacement paragraph. A marked-up version of the replacement paragraph is attached on a separate sheet. Please note that both the marked-up version and the clean version contain underlining that is to be retained and does not constitute an amendment.

~~EXAMPLE 2~~

~~Production of recombinant (r) CTAP-III, NAP-2, rTC-1, rTC-1\* and rTC-2.~~

A2  
From a human bone marrow CDNA library (Clontech, Palo Alto, USA) DNA coding for PBP was amplified in a PCR. 5' TATAGGATCCATGAGCCTCAGACTTGATAC CACC-3' (SEQ ID NO: 7) and 5' TATAGGATCCTCAATCAGCAGATTTCATCAC CTGCCAAT-3' (SEQ ID NO: 8) were used as forward, and reverse primers, respectively. BamHI restriction sites (underlined) were added to allow cloning in a suitable vector. A stop sequence (boldface) was included to allow proper transcription termination at the stage of protein expression. This PCR was performed using 2 ng of template DNA and Pfu DNA polymerase, which has proofreading capacity. The resulting product was of the expected size (400 bp). This product served as a template in a second PCR to produce the coding DNA of TC-1, TC-2, CTAP-III, NAP-2 and TC-1\*, a variant of TC-1 which lacks two C-terminal amino acids (Ala-Asp) and carries two additional N-terminal amino acids (Ala-Glu) (fig 2). These PCR products were cloned into expression vectors. For CTAP-III, NAP-2 and TC-1 the reverse primer was the same as the reverse primer described above. The forward primers were as follows:

for CTAP-III and TC-2:

5' GTGTAACATATGAACTTGGCGAAAGGCAAAGAG-3' (SEQ ID NO: 9);

for NAP-2 and TC-1\*;

5' GTGTAACATATGTATGCTGAACTCCGCTGCATG 3' (SEQ ID NO: 10);

and for TC-1:

~~5' GTGTAACATATGTATCTCCGCTGCATGTGTATAAAG-3' (SEQ ID NO: 11).~~